TRANDOLAPRIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trandolapril, and when can generic versions of Trandolapril launch?
Trandolapril is a drug marketed by Aurobindo Pharma, Chartwell Molecular, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Invagen Pharms, Lupin, Mylan, Teva Pharms, Watson Labs, and Glenmark Generics. and is included in eleven NDAs.
The generic ingredient in TRANDOLAPRIL is trandolapril; verapamil hydrochloride. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trandolapril
A generic version of TRANDOLAPRIL was approved as trandolapril; verapamil hydrochloride by GLENMARK GENERICS on May 5th, 2010.
Summary for TRANDOLAPRIL
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 18 |
Patent Applications: | 4,558 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TRANDOLAPRIL |
DailyMed Link: | TRANDOLAPRIL at DailyMed |
Recent Clinical Trials for TRANDOLAPRIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Nebraska | Phase 4 |
Hospital Authority, Hong Kong | Phase 4 |
Assaf-Harofeh Medical Center |
Pharmacology for TRANDOLAPRIL
Drug Class | Angiotensin Converting Enzyme Inhibitor |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for TRANDOLAPRIL
Paragraph IV (Patent) Challenges for TRANDOLAPRIL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MAVIK | Tablets | trandolapril | 1 mg, 2 mg and 4 mg | 020528 | 1 | 2004-10-04 |